Lineage Cell Therapeutics, Inc. (LCTX) Gross profit 2014–2023
Lineage Cell Therapeutics, Inc. (LCTX) annual gross profit history from SEC filings — each fiscal year as reported.
$8.3MFY2023 · since FY2014: $4.4M → $8.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | $8.3M | -40.8% |
| FY2022 | $14.0M | +379.4% |
| FY2021 | $2.9M | +102.3% |
| FY2020 | $1.4M | -53.6% |
| FY2019 | $3.1M | -33.8% |
| FY2018 | $4.7M | +42.4% |
| FY2017 | $3.3M | -40.9% |
| FY2016 | $5.6M | -6.1% |
| FY2015 | $5.9M | +34.5% |
| FY2014 | $4.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice